Osteoarthritis drug developer Paradigm says its purchase of an oral drug candidate won’t distract it from its key phase III knee trial. In a heavily back-ended deal, Paradigm will pay as much as $16.5 ...

Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Paradigm Biopharmaceuticals will spend up to $16.5 million on an oral drug asset, but stays focused on its ...